Elacestrant in Combination with Trastuzumab and Pertuzumab for the Treatment of Advanced Triple Positive Breast Cancer, ELATE Trial

Inclusion Criteria

• Female patients aged 18 years or older
• Should be able to provide the informed consent
• Histologically confirmed diagnosis of triple-positive breast cancer (ER+, PR+, HER2+). In the study, ER status will be considered positive if ≥ 10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry, with PR > 1%. Patients may be considered to be enrolled on study with prior approval of study principal investigator (PI) if ER > 10% and without progesterone receptor (PGR) positivity HER2 status will be considered positive with the score of 3+ with immunohistochemistry staining or 2+ by immunohistochemistry and fluorescence in situ hybridization (FISH)-amplified as per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (2023)
• Disease progression on or after at least one line of National Comprehensive Cancer Network (NCCN) recommended prior therapy
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Hemoglobin ≥ 9.0 g/dL, without transfusion or growth factors within 1 week
• Neutrophils ≥ 1.5 x 10^3/uL or ≥ 1.0 x 10^3/uL for participants with benign ethnic neutropenia
• Platelets ≥ 100 x 10^3/uL
• Patient must have a baseline left ventricular ejection fraction (LVEF) ≥ 50 % or ≥ institutional lower limit of normal (LLN) within 28 days prior to the study treatment
• Sex and contraceptive/barrier requirements * While on study treatment a participant must not breastfeed or be pregnant * Have a negative highly sensitive (eg, beta-human chorionic gonadotropin [β-hCG]) pregnancy test at screening and agree to further pregnancy tests per the protocol * Practice at least 1 highly effective method of contraception; if oral contraceptives are used, a barrier method of contraception must also be used * Female participants (pre- or perimenopausal) must use the appropriate highly effective, non-hormonal contraception method within 28 days of the first dose of study treatment, until 7 months after the last dose of study treatment (or longer based on companion drug). Highly effective methods of contraception are those methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include: ** Intrauterine device (IUD) ** Bilateral tubal occlusion ** Vasectomized partner ** Sexual abstinence (i.e., refraining from heterosexual intercourse during the study treatment and 120 days after the last dose of study treatment). * Unacceptable contraception methods: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea methods are not acceptable methods of contraception. Female condom and male condom should not be used together

Exclusion Criteria

• Prior treatment with a SERD
• Prior treatment with more than two lines of chemotherapy for metastatic disease, including antibody drug conjugates
• Untreated and/or active central nervous system (CNS) metastases
• History of other malignancies within the past 5 years (except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix)
• Inability to take oral medications, refractory or chronic nausea, gastrointestinal conditions (including significant gastric or bowel resection), history of malabsorption syndrome, or any other uncontrolled gastrointestinal condition that impact the absorption of the study drug
• Known intolerance to elacestrant or any of its excipients
• Uncontrolled active infection or intercurrent illness. * Patients with known hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection must have undetectable viral load during screening * Patients known to be HIV+ are allowed if they have undetectable viral load at baseline
• Patients who are on any of the prohibited medications
• Male participants will not be included because male breast cancer is rare and may differ biologically and hormonally, which would introduce heterogeneity difficult to address in a small, single arm phase II trial